ASCO Adds Jaw Osteonecrosis Recommendations to Bisphosphonate Guideline
The American Society of Clinical Oncology's updated guideline for the use of bisphosphonates in patients with multiple myeloma warns of osteonecrosis of the jaw as a potential adverse effect, and agrees with the recommendations in revised FDA labels for the bone-strengthening drugs
You may also be interested in...
Labeling for Roche/GlaxoSmithKline's once-monthly osteoporosis agent Boniva reflects upcoming class labeling for osteonecrosis and musculoskeletal pain risk with oral bisphosphonates
Further study of jaw osteonecrosis risk may differentiate Novartis' bisphosphonates Zometa and Aredia, FDA Division of Oncology Drug Products Director Richard Pazdur suggested
The International Fragrance Association North America took a break from its higher-stakes advocacy work Nov. 1 to give lawmakers and congressional staffers a "scent experience." Perfumers from six of the group's biggest members were on hand with "Scents of Home," joined by Monell Center researchers to educate attendees on the mechanics of scent and the important role it plays in people's lives.